Vaseem Mahboob Sells 6,995 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 6,995 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.68, for a total transaction of $172,636.60. Following the completion of the transaction, the chief financial officer directly owned 86,896 shares in the company, valued at $2,144,593.28. This represents a 7.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $26.40 on Friday. The firm’s 50 day simple moving average is $22.96 and its 200-day simple moving average is $22.57. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a one year low of $14.30 and a one year high of $30.00. The firm has a market cap of $1.55 billion, a PE ratio of -10.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. As a group, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on KMTS shares. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, BTIG Research raised their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $27.83.

Institutional Trading of Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies in the 4th quarter worth $31,000. Russell Investments Group Ltd. boosted its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies in the fourth quarter valued at about $72,000. BNP Paribas Financial Markets grew its stake in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.